Mr. Andre Larente reports

DIAGNOS PROVIDES ADDITIONAL INFORMATION ON AMENDMENT TO CONVERTIBLE DEBENTURES

Diagnos Inc. has provided additional information to the Feb. 28, 2025, announcement on amendment to convertible debentures.

One insider of the corporation, Andre Larente, is the beneficial owner of two convertible debentures being amended for a nominal aggregate value of $20,000. Assuming the conversion of the convertible debentures owned by him and exercise of all of his outstanding securities, Mr. Larente would own 2,188,115 common shares of the corporation representing 2.15 per cent of the total issued common shares, on a partially diluted basis. Mr. Larente is considered a related party of the corporation within the meaning of Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions (MI 61-101). The amendment to convertible debentures is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101, based on sections 5.5(a) and 5.7(1)(a), as the fair market value of the related party participation in the amendment to convertible debentures does not exceed 25 per cent of the corporation's current market capitalization. The board of directors of the corporation has reviewed and approved the amendment to convertible debentures to ensure that it was in the best interest of Diagnos and its shareholders.

The amendment to convertible debentures remains subject to the TSX Venture Exchange acceptance as well as execution of formal documentation. All monies quoted in this press release shall be stated and paid in lawful money of Canada.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging artificial intelligence, Diagnos aims to provide more information to health care clinicians to enhance diagnostic accuracy, streamline workflows and improve patient outcomes on a global scale.

We seek Safe Harbor.